Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor.

被引：7

作者：

Gu, Yi ^{[1
]}

Sai, Yang ^{[1
]}

Wang, Jian ^{[1
]}

Xia, Sumei ^{[1
]}

Wang, Guanglin ^{[1
]}

Zhao, Yuansheng ^{[1
]}

Zhang, Li ^{[1
]}

Yang, Wenqing ^{[1
]}

Dai, Guangxiu ^{[1
]}

Zhang, Weihan ^{[1
]}

Gong, Qisun ^{[1
]}

Tian, Zhenping ^{[1
]}

Su, Weiguo ^{[1
]}

机构：

[1] Hutchison MediPharma Ltd, Shanghai, Peoples R China

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-3371

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3371

引用

页数：1

共 50 条

[21] Dog pharmacokinetics and oral bioavailability of BN80915, a novel topoisomerase I inhibitor.
Pruñonosa, J
Lopez, S
Basart, D
Celma, C
Vilageliu, J
Obach, R
Peraire, C
Principe, P
CLINICAL CANCER RESEARCH, 1999, 5 : 3838S - 3838S
[22] Preclinical toxicology studies with Y15, a novel focal adhesion kinase (FAK) inhibitor.
Cance, William G.
Curtin, Leslie
Buitrago, Sandra
Golubovskaya, Vita
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[23] Exploratory study on predictive biomarkers for ARQ 092, a novel selective panAKT inhibitor.
Yu, Yi
Carazza, Rebecca
Chen, Chang-Rung
Isoyama, Takeshi
Tazaki, Koichi
Fujiwara, Kosaku
Dransfield, Daniel T.
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[24] PRECLINICAL PHARMACOKINETICS, DISPOSITION AND METABOLISM OF ICRF-187
MCPHERSON, E
ARCHILA, R
SCHEIN, PS
TEW, KD
MHATRE, RM
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 362 - 362
[25] Preclinical development of a novel, orally active cMet kinase inhibitor with potent antitumor and anti-angiogenic properties
Yang, Wei
Peek, Victoria
Uhlik, Mark
Pomeroy, Julie
Wu, Wenjuan
Chen, Yuefeng
Bi, Chen
Stephens, Jennifer
Weir, Spring
Huss, Karen
Credille, Kelly
Zhong, Boyu
Shih, Chuan
Yingling, Jonathan
CANCER RESEARCH, 2009, 69
[26] PHARMACOKINETICS AND DISPOSITION OF GR129574, A NOVEL PEPTIDE COLLAGENASE INHIBITOR, IN THE RAT
TIPPIN, T
STCLAIRE, R
LEE, FW
FASEB JOURNAL, 1994, 8 (04): : A99 - A99
[27] Novel calcium phosphate scale inhibitor.
Perez, LA
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 214 : 146 - COLL
[28] Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
Liu, Yahong
Cheng, Ying
Huang, Gongchao
Xia, Xiangying
Wang, Xingkai
Tian, Hongqi
FRONTIERS IN PHARMACOLOGY, 2023, 14
[29] Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.
Zanna, Claudio
Vaslin, Anne
Voss, Martin Henner
Heist, Rebecca Suk
Hierro, Cinta
Supko, Jeffrey G.
Nakai, Kiyohiko
Ishii, Nobuya
Menetrey, Annick
Roubaudi-Fraschini, Marie-Claude
Cordier, Julien
Douchain, Jerome
Nicolas-Metral, Valerie
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[30] Nonclinical metabolism, disposition, pharmacokinetics, and in vitro drug-drug interaction assessment of ARQ 087, a pan-FGFR inhibitor.
Hall, Terence G.
Volak, Laurie P.
Bresciano, Karen R.
Wang, Yunxia
Chen, Chang-Rung
Ali, Syed
Mckearn, David
Smukste, Inese
Savage, Ronald E.
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)

← 1 2 3 4 5 →